Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression: A Randomized Placebo-Controlled Clinical Trial

NCT06839144 is registered in ClinicalTrials.gov with Tel-Aviv Sourasky Medical Center as lead sponsor.

NCT NCT06839144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06839144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression: A Randomized Placebo-Controlled Clinical Trial
Lead sponsor
Tel-Aviv Sourasky Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2025
Completion date
August 31, 2026
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian cancer metastatic recurrent